FDA accepts Teva’s NDA for long-acting schizophrenia injection
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
This project is supported by the Irish Government through IDA Ireland
The new ECO grade is made using renewable feedstock
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated